Virological Non-Suppression, Non-Adherence and the Associated Factors Among People Living with HIV on Dolutegravir-Based Regimens: A Retrospective Cohort Study

References

• World Health Organization. People living with HIV People acquiring HIV People dying from HIV-related causes. World Health Organization; 2023:1–8. Available from: https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0294-who-hiv-epi-factsheet-v7.pdf. Accessed March 13, 2024.
   Google Scholar
• Musana H, Ssensamba JT, Nakafeero M, et al. Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda. AIDS Res Ther. 2021;18(1):1–10. doi:10.1186/s12981-021-00338-y
   PubMed Web of Science ®Google Scholar
• Ginat DT, Schaefer PW. Highly Active Antiretroviral Therapy (HAART). Neuroim Pharmacop. 2021;2021:203–212.
   Google Scholar
• UNAIDS. UNAIDS Data 2019. UNAIDS; 2019.
   Google Scholar
• Ba S, Ba ND, Sembene L, Dia H, Coulibaly M. Prevalence and factors associated with virologic failure among people living with HIV (PLHIV) monitored in a decentralized health care facility. Adv Infect Dis. 2019;2019:226–237.
   Google Scholar
• Mwau M, Syeunda CA, Adhiambo M, et al. Scale-up of Kenya’s national HIV viral load program: findings and lessons learned. PLoS One. 2018;13(1):e0190659. doi:10.1371/journal.pone.0190659
   PubMed Web of Science ®Google Scholar
• Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society–USA panel. JAMA. 2016;316(2):191. doi:10.1001/jama.2016.8900
   PubMed Web of Science ®Google Scholar
• Park TE, Mohamed A, Kalabalik J, Sharma R. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti Infect Ther. 2015;13(10):1195–1212. doi:10.1586/14787210.2015.1075393
   PubMed Web of Science ®Google Scholar
• Shah BM, Schafer JJ, Desimone JA. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2014;34(5):506–520. doi:10.1002/phar.1386
   PubMed Web of Science ®Google Scholar
• Mondi A, Cozzi-Lepri A, Tavelli A, et al. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019;22(1):e25227. doi:10.1002/jia2.25227
   PubMed Web of Science ®Google Scholar
• Alhassan Y, Twimukye A, Malaba T, et al. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. BMC Public Health. 2020;20(1). doi:10.1186/s12889-020-09991-w
   Web of Science ®Google Scholar
• Rolle CP, Nguyen V, Hinestrosa F, DeJesus E. Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV. AIDS Res Ther. 2021;18(1):1–11. doi:10.1186/s12981-021-00352-0
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD); 2018.
   Google Scholar
• Phillips AN, Venter F, Havlir D, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV. 2019;6(2):e116–27. doi:10.1016/S2352-3018(18)30317-5
   PubMed Web of Science ®Google Scholar
• Buju RT, Akilimali PZ, Kamangu EN, Mesia GK, Kayembe JMN, Situakibanza HN. Predictors of viral non-suppression among patients living with HIV under dolutegravir in Bunia, Democratic Republic of Congo: a prospective cohort study. Int J Environ Res Public Health. 2022;19:3.
   Web of Science ®Google Scholar
• Pena MJ, Chueca N, D’avolio A, Zarzalejos JM, Garcia F. Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment. Rare But Possible. 2018;2018:1.
   Google Scholar
• Pyngottu A, Scherrer AU, Kouyos R, et al. Predictors of virological failure and time to viral suppression of first-line integrase inhibitor–based antiretroviral treatment. Clin Infect Dis. 2021;73(7):e2134–41. doi:10.1093/cid/ciaa1614
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2021:594.
   Google Scholar
• de La Hoz JM, Bolaño L, Cárdenas O, et al. Characterization of treatment failure in HIV positive patients in the Colombian Caribbean region. Colomb Med. 2014;45(4):162–167. doi:10.25100/cm.v45i4.1566
   Web of Science ®Google Scholar
• Semengue ENJ, Fokam J, Etame N-K, et al. Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based first-line ART in Cameroon: an evidence of a successful transition model. Viruses. 2022;15(1):18. doi:10.3390/v15010018
   PubMed Web of Science ®Google Scholar
• D’Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. Aids. 2000;14(5):499–507. doi:10.1097/00002030-200003310-00005
   PubMed Web of Science ®Google Scholar
• Nabitaka VM, Nawaggi P, Campbell J, et al. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study. PLoS One. 2020;15(5):1–13. doi:10.1371/journal.pone.0232419
   Web of Science ®Google Scholar
• Siedner MJ, Moosa M-YS, McCluskey S. Resistance testing after virologic failure in sub-Saharan Africa: REVAMP clinical trial project design, methods and implementation status. Ann Internal Med. 2021;2021:1683–1692. doi:10.7326/M21-2229
   Google Scholar
• Afrane AKA, Goka BQ, Renner L, et al. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study. BMC Infect Dis. 2021;21(1):1–11. doi:10.1186/s12879-021-06459-z
   PubMed Web of Science ®Google Scholar
• Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816–826.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to Treat HIV. N Engl J Med. 2019;381(9):803–815. doi:10.1056/NEJMoa1902824
   PubMed Web of Science ®Google Scholar
• McCluskey SM, Pepperrell T, Hill A, Venter WDF, Gupta RK, Siedner MJ. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021;35(Suppl 2):S127–35. doi:10.1097/QAD.0000000000003082
   PubMedGoogle Scholar
• Fox MP, Berhanu R, Steegen K, et al. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016;21(9):1131–1137. doi:10.1111/tmi.12741
   PubMed Web of Science ®Google Scholar
• Pius A, Josephine NN, Erick S, et al. Influence of intensified adherence counselling on viral load suppression of people receiving antiretroviral therapy at a health centre IV in southwestern Uganda: a qualitative study. AIDS Res Ther. 2021;18(1):45. doi:10.1186/s12981-021-00372-w
   PubMed Web of Science ®Google Scholar
• Lukyamuzi Z, Etajak S, Katairo T, et al. Effect and implementation experience of intensive adherence counseling in a public HIV care center in Uganda: a mixed-methods study. BMC Infect Dis. 2021;21(1):1168. doi:10.1186/s12879-021-06862-6
   PubMed Web of Science ®Google Scholar
• Shoko C, Chikobvu D. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. BMC Infect Dis. 2019;19(1):169. doi:10.1186/s12879-019-3781-1
   PubMed Web of Science ®Google Scholar
• Byrd KK, Hou JG, Hazen R, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019;82(3):245–251. doi:10.1097/QAI.0000000000002142
   PubMed Web of Science ®Google Scholar
• Kikaire B, Ssemanda M, Asiimwe A, et al. HIV viral load suppression following intensive adherence counseling among people living with HIV on treatment at military-managed. Int J Infect Dis. 2021;112:45–51. doi:10.1016/j.ijid.2021.08.057
   PubMed Web of Science ®Google Scholar
• Oh KS, Han E. A comparison of medication adherence and viral suppression in antiretroviral treatment-naïve patients with HIV/AIDS depending on the drug formulary. PLoS One. 2021;16(1):e0245185. doi:10.1371/journal.pone.0245185
   PubMed Web of Science ®Google Scholar
• Atnafu GT, Moges NA, Wubie M, Gedif G. Incidence and predictors of viral load suppression after enhanced adherence counseling among HIV-Positive Adults in West Gojjam Zone, Amhara Region, Ethiopia. Infect Drug Resist. 2022;15:261–274. doi:10.2147/IDR.S341392
   PubMed Web of Science ®Google Scholar
• Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine. 2016;95(15):e3361. doi:10.1097/MD.0000000000003361
   PubMed Web of Science ®Google Scholar
• Cheng Y, Sauer B, Zhang Y, et al. Adherence and virologic outcomes among treatment-naïve veteran patients with human immunodeficiency virus type 1 infection. Medicine. 2018;97(2):e9430. doi:10.1097/MD.0000000000009430
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20(2):223–231. doi:10.1097/01.aids.0000199825.34241.49
   PubMed Web of Science ®Google Scholar
• von Wyl V, Klimkait T, Yerly S, et al. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. PLoS One. 2013;8(10):e77691. doi:10.1371/journal.pone.0077691
   PubMed Web of Science ®Google Scholar
• Abana CZ, Sagoe KWC, Bonney EY, et al. Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana. Medicine. 2019;98(6):e14313. doi:10.1097/MD.0000000000014313
   PubMed Web of Science ®Google Scholar
• Mehari Eden AbetuMuche EA, Gonete KA, Gonete KA. Virological suppression and its associated factors of dolutegravir based regimen in a resource-limited setting: an observational retrospective study in Ethiopia. HIV AIDS. 2021;13:709–717. doi:10.2147/HIV.S316776
   Google Scholar
• Schramm B, Temfack E, Descamps D, et al. Viral Suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. Lancet HIV. 2022;9:e544–53. doi:10.1016/S2352-3018(22)00136-9
   PubMed Web of Science ®Google Scholar
• Nabukeera S, Kagaayi J, Makumbi FE, Mugerwa H, Matovu JKB. Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the joint clinical research centre in Lubowa, Kampala Uganda. PLoS One. 2021;16(1):e0246140. doi:10.1371/journal.pone.0246140
   PubMed Web of Science ®Google Scholar
• Maena J, Banke-Thomas A, Mukiza N, et al. Determinants of viral load non-suppression among adolescents in Mbale District, Eastern Rural Uganda. AIDS Res Ther. 2021;18(1):91. doi:10.1186/s12981-021-00408-1
   PubMed Web of Science ®Google Scholar
• Berihun H, Bazie GW, Beyene A, Zewdie A, Kebede N. Viral suppression and associated factors among children tested for HIV viral load at Amhara public health institute, Dessie Branch, Ethiopia: a cross-sectional study. BMJ Open. 2023;13(1):e068792. doi:10.1136/bmjopen-2022-068792
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. Alcohol Res Heal. 2010;33(3):280–287.
   PubMedGoogle Scholar
• Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202. doi:10.1097/QAI.0b013e3181b18b6e
   PubMed Web of Science ®Google Scholar
• Kim JY, Yang Y, Kim HK, Kim JY. The impact of alcohol use on antiretroviral therapy adherence in Koreans living with HIV. Asian Nurs Res. 2018;12(4):258–264. doi:10.1016/j.anr.2018.10.002
   PubMed Web of Science ®Google Scholar
• Tran BX, Nguyen LT, Do CD, Le Nguyen Q, Maher RM. Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. BMC Public Health. 2014;14(1):27. doi:10.1186/1471-2458-14-27
   PubMedGoogle Scholar
• Velloza J, Kemp CG, Aunon FM, Ramaiya MK, Creegan E, Simoni JM. Alcohol use and antiretroviral therapy non-adherence among adults living with HIV/AIDS in Sub-Saharan Africa: a systematic review and meta-analysis. AIDS Behav. 2020;24(6):1727–1742. doi:10.1007/s10461-019-02716-0
   PubMed Web of Science ®Google Scholar
• Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640. doi:10.7448/IAS.16.3.18640
   PubMed Web of Science ®Google Scholar
• Jones HS, Floyd S, Stangl A, et al. Association between HIV stigma and antiretroviral therapy adherence among adults living with HIV: baseline findings from the HPTN 071 (PopART) trial in Zambia and South Africa. Trop Med Int Heal. 2020;25(10):1246–1260. doi:10.1111/tmi.13473
   PubMed Web of Science ®Google Scholar
• Nurfalah F, Yona S, Waluyo A. The relationship between HIV stigma and adherence to antiretroviral (ARV) drug therapy among women with HIV in Lampung, Indonesia. Enfermería Clínica. 2019;29:234–237. doi:10.1016/j.enfcli.2019.04.138
   Web of Science ®Google Scholar
• Tiyou A, Belachew T, Alemseged F, Biadgilign S. Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest Ethiopia. AIDS Res Ther. 2010;7(1):39. doi:10.1186/1742-6405-7-39
   PubMed Web of Science ®Google Scholar
• Kalichman SC, Kalichman MO, Cherry C. Forget about forgetting: structural barriers and severe non-adherence to antiretroviral therapy. AIDS Care. 2017;29(4):418–422. doi:10.1080/09540121.2016.1220478
   PubMed Web of Science ®Google Scholar
• Freeman R, Gwadz M, Francis K, Hoffeld E. Forgetting to take HIV antiretroviral therapy: a qualitative exploration of medication adherence in the third decade of the HIV epidemic in the United States. SAHARA J J Soc Asp HIV/AIDS Res Alliance. 2021;18(1):113–130. doi:10.1080/17290376.2021.1989021
   PubMed Web of Science ®Google Scholar
• Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–784. doi:10.1007/s10461-009-9533-2
   PubMed Web of Science ®Google Scholar
• Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438. doi:10.1371/journal.pmed.0030438
   PubMed Web of Science ®Google Scholar
• Chukwuma A, Oladele Ademola A, Omotoso Ibrahim M, et al. Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a tertiary hospital in Ilorin, Nigeria. Pan Afr Med J. 2019;32:10.
   Web of Science ®Google Scholar
• Achappa B, Madi D, Bhaskaran U, Ramapuram JT, Rao S, Mahalingam S. Adherence to antiretroviral therapy among people living with HIV. N Am J Med Sci. 2013;5(3):220–223. doi:10.4103/1947-2714.109196
   PubMedGoogle Scholar
• Tegegne D, Mamo G, Negash B, Habte S, Gobena T, Letta S. Poor adherence to highly active antiretroviral therapy and associated factors among people living with HIV in Eastern Ethiopia. SAGE Open Med. 2022;10:20503121221104428. doi:10.1177/20503121221104429
   Web of Science ®Google Scholar
• Mutagonda RF, Mlyuka HJ, Maganda BA, Kamuhabwa AAR. Adherence, effectiveness and safety of dolutegravir based antiretroviral regimens among HIV infected children and adolescents in Tanzania. J Int Assoc Provid AIDS Care. 2022;21:23259582221109612. doi:10.1177/23259582221109613
   Google Scholar